Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis

Hay Fever Clinical Trial

Official title:

A Multicentre, International, Randomised, Double-blind, Placebo-controlled Study to Demonstrate the Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03724240
• Other study ID #: ABT-gpASIT011
• Secondary ID: 2017-002911-33
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: January 2, 2019
• Est. completion date: December 2019

Study information

• Verified date: October 2018
• Source: ASIT Biotech S.A.
• Contact: Remy Von Frenckell, clinDev
• Phone: 0032 2 264 03 90
• Email: remy.vonfrenckell[@]biotech.be
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomised, double-blind, placebo-controlled, international, multicentre, confirmatory Phase III study in patients with grass pollen-related allergic rhinoconjunctivitis. After having given written informed consent, the patients will be examined to establish eligibility according to inclusion/exclusion criteria. The eligible patients will be randomised to Placebo or gpASIT+™ treatment according to a 1:1 ratio. Study treatment will be administered before the start of the pollen season in 2019

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 624
• Est. completion date: December 2019
• Est. primary completion date: September 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• Allergy diagnosis:

• A clinical history of moderate to severe grass pollen-induced Seasonal Allergic Rhinoconjunctivitis (SARC) for at least 2 pollen seasons, requiring treatment with either antihistamines or nasal corticosteroids during the 2017 and 2018 grass pollen seasons and with symptoms interfering with usual daily activities or with sleep, as defined according to Allergic Rhinitis and its Impact on Asthma (ARIA) classification of rhinitis (Bousquet et al. 2001)

• A positive Skin Prick Test (SPT) (wheal diameter =3 mm) to grass pollen mixture, histamine wheal =3 mm, sodium chloride (NaCl) control reaction <2 mm AND

• Specific IgE against grass pollen =0.7 kU/L. 6)

• For asthmatic patients, confirmed diagnosis of controlled asthma according to Global Initiative for Asthma (GINA; 2018)

Exclusion Criteria:

• Diagnosis of mastocytosis;

• Previous (within the last 5 years) immunotherapy with grass allergens;

• Ongoing immunotherapy with grass allergens or any other allergens;

• Patients with any history of anaphylaxis due to any cause;

• Patients with a history of hypersensitivity to the excipients of the investigational product;

• Patients with a forced expiratory volume in 1 second (FEV1) <80% of the predicted value (European Community for Steel and Coal) or with a peak expiratory flow (PEF) <70% of the individual optimum value at the Screening visit;

• History of being intubated with mechanical ventilator support or in intensive care unit for asthma at any point in the patient's life;

• History of emergency visit or hospital admission for asthma in the previous 12 months;

• Clinical history of moderate to severe allergic rhinitis, as defined according to the ARIA classification of rhinitis, due to tree pollen near or overlapping the grass pollen season;

• Clinical history of moderate to severe allergic rhinitis as defined according to the ARIA classification of rhinitis caused by an allergen to which the participant is regularly exposed;

Related Conditions & MeSH terms

• Conjunctivitis, Allergic
• Hay Fever
• Rhinitis, Allergic, Seasonal

Intervention

Biological:
• Placebo solution
4 x 2 injection over 21 days the dosage is100 µg/ml
• gpASIT+TM
4 x 2 injection over 21 days the dosage is100 µg/ml

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
ASIT Biotech S.A.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Average daily Combined Symptom and Medication Score collected during the peak of the grass pollen season	Symptoms are measured on a scale from 0 to 3- No symptoms= 0 mild symptoms=1 moderate symptoms =2 severe symptoms =3. Daily symptom score is calculated as: daily RTSS/6.; Medication score: No rescue medications used =0 Tablet of antihistamine = 1 Nasal spray of fluticasone propionate with or without antihistamine= 2 Tablet of methylprednisolone with or without antihistamine/ fluticasone propionate= 3 Maximum daily Rescue Medication Score (RMS):3 CSMS= dSS (daily symptom score) (0-3) + dMS (daily medication score)(0-3)= 0-6 The daily symptom score and the daily RMS each range from 0 to 3 and, thus, the daily CSMS ranges from 0 to 6. The average CSMS of the peak of the grass pollen season or the whole grass pollen season will be calculated, per patient, as the sum of the daily CSMS within the peak of pollen season or the whole pollen season divided by the number of days of the peak pollen season or the whole pollen season, respectively (as defined by Pfaar et al. 2014).	the patients assessed up to 9 months. [Safety Issue: No]
Secondary	Combined symptom and medication score (CSMS) over the entire grass pollen season	Symptoms are measured on a scale from 0 to 3- No symptoms= 0 mild symptoms=1 moderate symptoms =2 severe symptoms =3. Daily symptom score is calculated as: daily RTSS/6.; Medication score: No rescue medications used =0 Tablet of antihistamine = 1 Nasal spray of fluticasone propionate with or without antihistamine= 2 Tablet of methylprednisolone with or without antihistamine/ fluticasone propionate= 3 Maximum daily Rescue Medication Score (RMS):3 CSMS= dSS (daily symptom score) (0-3) + dMS (daily medication score)(0-3)= 0-6 The daily symptom score and the daily RMS each range from 0 to 3 and, thus, the daily CSMS ranges from 0 to 6. The average CSMS of the peak of the grass pollen season or the whole grass pollen season will be calculated, per patient, as the sum of the daily CSMS within the peak of pollen season or the whole pollen season divided by the number of days of the peak pollen season or the whole pollen season, respectively (as defined by Pfaar et al. 2014).	the patients assessed up to 9 months. [Safety Issue: No]
Secondary	Symptom subscores (eyes and nose) over the peak period and the entire grass pollen season	Symptom scores for nose (rhinorrhoea, sneezing, nasal pruritus, nasal congestion) and eye (ocular pruritus, watery eyes) symptoms will be collected on a daily basis, using a four-point ordinal scale.; Nasal symptoms: (Score 0-3) 0 = no symptoms; = mild symptoms (sign/symptom clearly present, but minimal awareness; easily tolerated); = moderate symptoms (definite awareness of sign/symptom that is bothersome but tolerable); = severe symptoms (sign/symptom that is hard to tolerate; causes interference with activities of daily living and/or sleeping) Itchy nose:0-3 Sneezing:0-3 Runny nose:0-3 Blocked nose:0-3; Conjunctival symptoms: Itchy/red eyes:0-3 Watery eyes:0-3	the patients assessed up to 9 months. [Safety Issue: No]
Secondary	Total Symptom Score (TSS: the sum of the eyes, nose and lung symptom scores) in asthmatic patients only over the peak period and the entire grass pollen season	The daily Rhinoconjunctivitis Total Symptom Score (RTSS) will correspond to the sum of the six nose and eye symptoms (score ranging from 0 to 18). Then, daily symptom score is calculated as: daily RTSS/6.The common rating system is the following: 0 = no symptoms; 1 = mild symptoms (sign/symptom clearly present but minimal awareness, easily tolerated); 2 = moderate symptoms (definite awareness of any sign/symptom that is bothersome but tolerated); 3 = severe symptoms (sign/symptom that is hard to tolerate, causing interference with activities of daily living and/or sleeping) as defined by Pfaar et al. 2014	the patients assessed up to 9 months. [Safety Issue: No]
Secondary	Use of rescue medication to relieve asthma symptoms in asthmatic patients	Patients will be instructed to use the rescue medications according to the following standardised and stepwise procedure: 1. In first instance: oral H1 antihistamine (desloratadine, one 5 mg tablet/day); 2. If Step 1 fails or is insufficient, intranasal corticosteroid: fluticasone propionate (50 µg/dose, one puff/nostril as needed) (alone or combined with oral antihistamine); 3. If Step 2 fails: oral corticosteroid (methylprednisolone 16 mg tablet, one tablet/day for a maximum of 3 days).	the patients assessed up to 9 months. [Safety Issue: No]
Secondary	Number (%) of "well days"	A "well day" is a day for which the patient does not report any intake of any rescue medication ( RMS = 0) and with no Grade =2 individual eye or nose symptom and overall Rhinoconjunctivitis Total Symptom Score (RTSS) =2.	the patients assessed up to 9 months. [Safety Issue: No]
Secondary	Standardised Rhinoconjunctivitis Quality of Life Questionnaire in all patients	to measure the functional impairments of the patients resulting from their rhinoconjunctivitis in their day-to-day life (Juniper et al. 1999)-The validated RQLQ has 28 questions in 7 domains (activity limitation, sleep problems, nose symptoms, eye symptoms, non-nose/eye symptoms, practical problems and emotional function). There are 3 'patient-specific' questions in the activity domain which allow patients to select 3 activities in which they are most limited by their rhinoconjunctivitis. Patients recall how bothered they have been by their rhinoconjunctivitis during the previous week and to respond to each question on a 7-point scale (0 = not impaired at all - 6 = severely impaired). The overall RQLQ score is the mean of all 28 responses and the individual domain scores are the means of the items in those domains.	the patients assessed up to 9 months. [Safety Issue: No]
Secondary	Patient's Global Efficacy (PGE) assessment.	At the end of the study, the patients will be asked how they have felt overall during the study grass pollen season compared to previous grass pollen seasons ("much better", "better", "the same", "worse", "much worse"	the patients assessed up to 9 months. [Safety Issue: No]
Secondary	Number of working days lost due to grass pollen-induced allergy symptoms	Absenteeism, evaluated by recording the number of working days lost due to grass pollen-induced allergic rhinoconjunctivitis	the patients assessed up to 9 months. [Safety Issue: No]
Secondary	Systemic allergic reactions <30 minutes after investigational product administration	Immediate and delayed systemic reactions will be graded according to the World Allergy Organisation classification (Cox et al. 2010).	up to 4 months ( safety issue:No)
Secondary	Local reactions at the injection site (swelling and redness) after investigational product administration	local reaction (wheal diameter) is 5 to 8 cm	up to 4 weeks [Safety Issue: Yes]
Secondary	Other treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)	A TEAE is defined as an event that emerges during treatment having been absent pre-treatment, or which worsens relative to the pre-treatment state.Adverse Events will be tabulated by System Organ Class (SOC) and Preferred Term (PT) after medical coding using MedDRA	up to 8 months [Safety Issue: Yes]
Secondary	Induction of grass pollen-specific Immunoglobulin: IgE, IgG and IgG4 in serum of all patients	In all patients at all sites, 2 mL of blood will be withdrawn for the measurement of grass pollen-specific IgE, IgG4 and IgG in serum sites. Grass pollen-specific IgE, IgG and IgG4 measurements in patient serum will be assessed by ImmunoCAP® method in a central laboratory	up to 8 months [Safety Issue: No]